Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6656541 | 0.79 | POLB (0.32) | POLB | |
| SCHEMBL2947259 | 0.78 | ALDH1A1 (0.32) | ALDH1A1TSHRPOLB | |
| SCHEMBL5512354 | 0.75 | FAAH (0.32) | — | |
| SCHEMBL12927421 | 0.74 | — | — | |
| SCHEMBL12884950 | 0.74 | CA12 (0.35) | — | |
| SCHEMBL14113105 | 0.72 | — | — | |
| SCHEMBL5512327 | 0.72 | CHRNB2 (0.40) | — | |
| SCHEMBL5516478 | 0.72 | MVD (0.32) | TSHR | |
| SCHEMBL1106444 | 0.72 | — | — | |
| SCHEMBL18907738 | 0.71 | RAB9A (0.36) | ALDH1A1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| WO-2022095756-A1 | MUTANT IDH1 AND IDH2 INHIBITOR AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2022-05-12 | — | — | WO | disclosed |
| US-20210122739-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-04-29 | — | — | US | disclosed |
| US-20210078951-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-20200323858-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-10-15 | — | — | US | disclosed |
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-10646492-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-05-12 | — | — | US | disclosed |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-4461887-A | AND PIPERAZINE FORMING POLYAMIDES | POLAROID CORPORATION (US) | 1984-07-24 | — | — | US | disclosed |
| US-4393196-A | POLYACYLHYDRAZIDES, OPTICAL FILTERS, POLARIZERS | POLAROID CORPORATION (US) | 1983-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3232/4885TSHR 3486/4885POLB 1792/4885 |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3232/4885TSHR 3486/4885POLB 1792/4885 |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3232/4885TSHR 3486/4885POLB 1792/4885 |
| US-20210122739-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, PYCARD, NOD1 | ALDH1A1 1660/4885TSHR 4076/4885POLB 4857/4885 |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3232/4885TSHR 3486/4885POLB 1792/4885 |
| US-20210078951-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ALDH1A1 686/4885TSHR 3035/4885POLB 2003/4885 |
| US-10646492-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3232/4885TSHR 3486/4885POLB 1792/4885 |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3232/4885TSHR 3486/4885POLB 1792/4885 |
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | ACACA, ACACB, ACAT1 | ALDH1A1 203/4885TSHR 4028/4885POLB 1760/4885 |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | ALDH1A1 2162/4885TSHR 4305/4885POLB 3064/4885 |
| US-20200323858-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3232/4885TSHR 3486/4885POLB 1792/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3232/4885TSHR 3486/4885POLB 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.